GLP-1 receptor agonists modulate dopaminergic signaling by increasing dopamine--hydroxylase levels, reducing dopamine release, enhancing dopamine transporter expression, increasing dopamine turnover, and suppressing NAc projections, which attenuates phasic dopaminergic signaling and reduces consummatory behaviors (Eren-Yazicioglu et al., 2021)
Thank you for making a great flavor.* Was this helpful
Patient safety and individualized care remain our priority
Comparing These Four Peptides | Compound | Primary Target | Main Effect | |---|---|---| | Sermorelin | GHRH Receptor | Stimulates endogenous GH release | | CJC-1295 | GHRH Receptor | Sustained GH stimulation | | Ipamorelin | Ghrelin Receptor (GHS-R1a) | Triggers GH secretion | | IGF-1 LR3 | IGF-1 Receptor | Direct tissue-level IGF signaling | For a deeper dive into the specific compounds available, see our Peptide Therapy Education page, which catalogs 23 active peptide compounds with full mechanism-of-action references
Intense exercise for 30 minutes a day, at least three times a week, enhances the body's antioxidant defense
Caffeine effects on systemic metabolism, oxidative-inflammatory pathways, and exercise performance